Cyclooxygenase-2 (COX-2) is also upregulated in osteomyelitis; its inhibitor celecoxib mitigates bone loss by modulating immune cell populations (e.g., reducing MDSCs) and inhibiting osteoclastogenesis (Chen Y. et al., 2025). Here, PTGS2 is linked to osteomyelitis.